TY - JOUR
T1 - Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
AU - Corazzelli, Gaetano
AU - Frigeri, Ferdinando
AU - Arcamone, Manuela
AU - Aloj, Luigi
AU - Capobianco, Gaetana
AU - Becchimanzi, Cristina
AU - Morelli, Emanuela
AU - Volzone, Francesco
AU - Marcacci, Gianpaolo
AU - Russo, Filippo
AU - De Filippi, Rosaria
AU - Lastoria, Secondo
AU - Pinto, Antonio
PY - 2011/12
Y1 - 2011/12
N2 - Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120mg/m
2 every 21d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
AB - Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120mg/m
2 every 21d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
KW - Fotemustine
KW - Nitrosourea
KW - Salvage therapy
KW - Sezary syndrome
KW - T-cell lymphomas
UR - http://www.scopus.com/inward/record.url?scp=81255127575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81255127575&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2011.01683.x
DO - 10.1111/j.1600-0609.2011.01683.x
M3 - Article
C2 - 21752099
AN - SCOPUS:81255127575
VL - 87
SP - 547
EP - 553
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 6
ER -